Home > Insider Trading > Filing (0001209191-20-028070)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501756	Adverum Biotechnologies Inc.	ADVM	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1233539	D Leone Patterson	C/O Adverum Biotechnologies, Inc. 800 Saginaw Drive Redwood City CA 94063	Ceo, President And Director	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-05-06	20,000	$3.44	143,659	No	4	M	Direct
Common Stock	Disposition	2020-05-06	20,000	$20.02	123,659	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-05-06	20,000	$0.00	20,000	$3.44

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
155,576		2026-06-15	No	4	M	Direct

Footnotes

The balance of shares reflected in Reporting Person's prior Form 4 was inadvertently reflected as 123,429 shares and should have been reflected as 123,659 shares. The Form 4 originally reflecting the incorrect balance, filed with the SEC on 2/10/2020, has been amended to reflect the correct end of period balance in Column 5 of Table I in that filing.
This transaction was pursuant to a 10b5-1 Plan.
Represents weighted average sales price. The shares were sold at prices ranging from $20.00 to $20.09. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Twenty-Five Percent (25%) of the total shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48 of the total shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall be vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.